Highly Active Antiretroviral Therapy and the Epidemic of HIV+ End-Stage Renal Disease
Open Access
- 1 August 2005
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 16 (8), 2412-2420
- https://doi.org/10.1681/asn.2005040340
Abstract
The rise in the number of patients with HIV-associated nephropathy and HIV-infection with end-stage renal disease (HIV+ ESRD) continues to be a substantial concern for the ESRD program. In order to assess the impact of highly active antiretroviral therapy (HAART) on the progression of patients with AIDS to the development of ESRD and to project the prevalence of HIV+ ESRD through 2020, a mathematical model of the dynamics of HIV+ infection in the ESRD population was developed. Epidemiologic data on AIDS and HIV+ ESRD among black individuals in the United States were obtained since 1991 from the Centers for Disease Control and Prevention and US Renal Data System, respectively. The model was constructed to predict the prevalence of HIV+ ESRD incorporating the current rate of growth in AIDS prevalence. Two possible trends were considered: linear AIDS growth and exponential AIDS growth. The likely effectiveness of HAART in slowing progression to HIV+ ESRD was estimated from the best fit of the model to the data after 1995, when HAART was introduced. The model was then used to evaluate recent data and to project the prevalence of HIV+ ESRD through 2020. The model suggested that HAART has reduced the rate of progression from AIDS to HIV+ ESRD by 38%. The model projected an increase in HIV+ ESRD prevalence in the future as a result of the increase in the AIDS population among black individuals. This increase was predicted even assuming a 95% reduction in the progression from AIDS to HIV+ ESRD. Despite the potential benefit of HAART, the prevalence of HIV+ ESRD in the United States is expected to rise in the future as a result of the expansion of the AIDS population among black individuals. It is concluded that prevention of progression to ESRD should focus on early antiretroviral treatment of HIV-infected patients who have evidence of HIV-associated nephropathy.Keywords
This publication has 26 references indexed in Scilit:
- Association between Renal Disease and Outcomes among HIV-Infected Women Receiving or Not Receiving Antiretroviral TherapyClinical Infectious Diseases, 2004
- The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infectionKidney International, 2004
- Is There an Epidemic of HIV Infection in the US ESRD Program?Journal of the American Society of Nephrology, 2004
- Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathyAIDS, 2004
- HIV-Associated Nephropathy: Case Study and Review of the LiteratureAIDS Patient Care and STDs, 2000
- HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infectionKidney International, 1999
- Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.JCI Insight, 1997
- Captopril and renal survival in patients with human immunodeficiency virus nephropathyAmerican Journal of Kidney Diseases, 1996
- Nephropathy Associated with Infection by Human Immunodeficiency Virus: A Report on 11 Cases Including 6 Treated with ZidovudineNephron, 1992